Institute for Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, Massachusetts.
University of Massachusetts Medical School, Worcester, Massachusetts.
J Hosp Med. 2019 Dec 1;14(12):729-736. doi: 10.12788/jhm.3270. Epub 2019 Jul 24.
In patients hospitalized with heart failure (HF) exacerbations, physicians routinely supplement potassium to maintain levels ≥4.0 mEq/L. The evidence basis for this practice is relatively weak. We aimed to evaluate the association between serum potassium levels and outcomes in patients hospitalized with HF.
We identified patients admitted with acute HF exacerbations to hospitals that contributed to an electronic health record-derived dataset. In a subset of patients with normal admission serum potassium (3.5-5.0 mEq/L), we averaged serum potassium values during a 72-hour exposure window and categorized as follows: <4.0 mEq/L (low normal), 4.0-4.5 mEq/L (medium normal), and >4.5 mEq/L (high normal). We created multivariable models examining associations between these categories and outcomes.
We included 4,995 patients: 2,080 (41.6%), 2,326 (46.6%), and 589 (11.8%) in the <4.0, 4.0-4.5, and >4.5 mEq/L cohorts, respectively. After adjustment for demographics, comorbidities, and presenting severity, we observed no difference in outcomes between the low and medium normal groups. Compared to patients with levels <4.0 mEq/L, patients with a potassium level of >4.5 mEq/L had a longer length of stay (median of 0.6 days; 95% CI = 0.1 to 1.0) but did not have statistically significant increases in mortality (OR [odds ratio] = 1.51; 95% CI = 0.97 to 2.36) or transfers to the intensive care unit (OR = 1.78; 95% CI = 0.98 to 3.26).
Inpatients with heart failure who had mean serum potassium levels of <4.0 showed similar outcomes to those with mean serum potassium values of 4.0-4.5. Compared with mean serum potassium level of <4.0, mean serum levels of >4.5 may be associated with increased risk of poor outcomes.
在因心力衰竭(HF)恶化而住院的患者中,医生通常会补充钾以维持水平≥4.0 mEq/L。这种做法的证据基础相对较弱。我们旨在评估住院 HF 患者血清钾水平与结局之间的关系。
我们确定了因急性 HF 恶化而入住参与电子病历衍生数据集的医院的患者。在一组血清钾正常入院的患者(3.5-5.0 mEq/L)中,我们平均了 72 小时暴露窗期间的血清钾值,并分为以下几类:<4.0 mEq/L(低正常)、4.0-4.5 mEq/L(中正常)和>4.5 mEq/L(高正常)。我们创建了多变量模型,以检查这些类别与结局之间的关系。
我们纳入了 4995 名患者:<4.0、4.0-4.5 和>4.5 mEq/L 组分别有 2080 名(41.6%)、2326 名(46.6%)和 589 名(11.8%)。在调整了人口统计学、合并症和就诊严重程度后,我们在低正常组和中正常组之间未观察到结局差异。与血清钾水平<4.0 mEq/L 的患者相比,血清钾水平>4.5 mEq/L 的患者住院时间更长(中位数为 0.6 天;95%CI=0.1 至 1.0),但死亡率无统计学显著增加(OR[比值比]=1.51;95%CI=0.97 至 2.36)或转入重症监护病房(OR=1.78;95%CI=0.98 至 3.26)。
血清钾平均水平<4.0 的 HF 住院患者的结局与血清钾平均水平为 4.0-4.5 的患者相似。与血清钾平均水平<4.0 相比,平均血清水平>4.5 可能与不良结局风险增加相关。